# US 9,433,603 B2 · Use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,433,603 B2 - Document ID: US9433603B2 - Status: Granted - Kind: B2 - Application number: 14/344,154 - Filed: 2012-09-13 - Published: 2014-08-21 - Granted: 2016-09-06 - Earliest claimed: 2011-09-13 - Assignees: Pierre Fabre Medicament - Applicants: Bernard Vacher; Bruno Le Grand - Inventors: Bernard Vacher; Bruno Le Grand - Web page: https://patentgrep.com/patent/US9433603B2 ## CPC - A61K 31/39: having oxygen in the same ring - A61P 9/00: Drugs for disorders of the cardiovascular system - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to the use of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or a pharmaceutically acceptable salt thereof for preventing and/or treating cardiotoxic effects caused by chemotherapy and/or radiation. ## Claims ### Claim 1 A method for preventing the cardiotoxic effects due to doxorubicin by administration to a patient in need thereof of an effective amount of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of its pharmaceutically acceptable salts. ### Claim 2 (depends on 1) The method according to claim 1, wherein the cardiotoxic effects translate as rhythm disorders, cardiac ischemia, systolic cardiac dysfunction, pericarditis, thrombophilia, and/or heart failure. ### Claim 3 (depends on 1) The method according to claim 1, wherein the patient does not currently suffer from cardiovascular disease. ### Claim 4 (depends on 1) The method according to claim 1, wherein the patients are treated cancer patients who are young or elderly and/or suffering from cardiovascular disease and/or accumulating cardiovascular risk factors. ### Claim 5 (depends on 1) The method according to claim 1, wherein the patients are treated cancer patients having a ventricular ejection fraction or left ventricular ejection fraction lower than normal on initiation of anticancer treatment, or those having a ventricular ejection fraction which decreases throughout the course of this treatment. ### Claim 6 A method for preventing the cardiotoxic effects due to doxorubicin by administration to a patient in need thereof of an effective amount of a pharmaceutical composition containing, as active ingredient, 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient. ### Claim 7 (depends on 6) The method according to claim 6, wherein the cardiotoxic effects translate as rhythm disorders, cardiac ischemia, systolic cardiac dysfunction, pericarditis, thrombophilia, and/or heart failure. ### Claim 8 (depends on 6) The method according to claim 6, wherein the patient does not currently suffer from cardiovascular disease. ### Claim 9 (depends on 6) The method according to claim 6, wherein the patients are treated cancer patients having a ventricular ejection fraction or left ventricular ejection fraction lower than normal on initiation of the anticancer treatment, or those having a ventricular ejection fraction which decreases throughout the course of this treatment. ### Claim 10 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is administrated via oral or intravenous route. ### Claim 11 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is administrated simultaneously with doxorubicin. ### Claim 12 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is administrated separately or sequentially in relation to doxorubicin. ### Claim 13 (depends on 6) The method according to claim 6, wherein the pharmaceutical composition is in the form of a daily dosage unit of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of its pharmaceutically acceptable salts, of between 1 and 1000 mg. ### Claim 14 A method for preventing pericarditis or thrombophilia due to doxorubicin by administration to a patient in need thereof of an effective amount of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of its pharmaceutically acceptable salts. ### Claim 15 (depends on 14) The method according to claim 14, wherein the patients are treated cancer patients who are young or elderly and/or suffering from cardiovascular disease and/or accumulating cardiovascular risk factors. ### Claim 16 (depends on 14) The method according to claim 14, wherein the patients are treated cancer patients having a ventricular ejection fraction or left ventricular ejection fraction lower than normal on initiation of anticancer treatment, or those having a ventricular ejection fraction which decreases throughout the course of this treatment. ### Claim 17 A method for preventing pericarditis or thrombophilia due to doxorubicin by administration to a patient in need thereof of an effective amount of a pharmaceutical composition containing, as active ingredient, 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of its pharmaceutically acceptable salts and at least one pharmaceutically acceptable excipient. ### Claim 18 (depends on 17) The method according to claim 17, wherein the patients are treated cancer patients having a ventricular ejection fraction or left ventricular ejection fraction lower than normal on initiation of the anticancer treatment, or those having a ventricular ejection fraction which decreases throughout the course of this treatment. ### Claim 19 (depends on 17) The method according to claim 17, wherein the pharmaceutical composition is administrated via oral or intravenous route. ### Claim 20 (depends on 17) The method according to claim 17, wherein the pharmaceutical composition is administrated simultaneously with doxorubicin. ### Claim 21 (depends on 17) The method according to claim 17, wherein the pharmaceutical composition is administrated separately or sequentially in relation to doxorubicin. ### Claim 22 (depends on 17) The method according to claim 17, wherein the pharmaceutical composition is in the form of a daily dosage unit of 3-(R)-[3-(2-methoxyphenylthio)-2-(S)-methyl-propyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine or one of its pharmaceutically acceptable salts, of between 1 and 1000 mg.